Shots trigger exceptional antibody response by activating key helper immune cells.
By WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
The first two vaccines created with mRNA vaccine technology — the Pfizer/BioNTech and Moderna COVID-19 vaccines — are arguably two of the most effective COVID vaccines developed to date. In clinical trials, both were more than 90% effective at preventing symptomatic infection, easily surpassing the 50% threshold the Food and Drug Administration had set for COVID-19 vaccines to be considered for emergency use authorization.
While
breakthrough infections have increased with the emergence of the delta and
omicron variants, the vaccines remain quite effective at preventing
hospitalizations and deaths. The success of the new technology has led
scientists to try to figure out why mRNA vaccines are so effective and whether
the protection they provide is likely to endure as new variants arise.
A new study from researchers at Washington University School of Medicine in St. Louis and St. Jude Children’s Research Hospital shines light on the quality of the immune response triggered by mRNA vaccines.
The study shows that the Pfizer vaccine strongly and persistently activates a kind of helper immune cell that assists antibody-producing cells in creating large amounts of increasingly powerful antibodies, and also drives the development of some kinds of immune memory.









